PacBio Revio vs Nanopore PromethION

Since April 2025, 535 bioRxiv and medRxiv preprints say they used Revio and 887 PromethION; 95 used both. Updated daily (as of Nov 16)

PromethION is used 1.5x more often than Revio.

In Jun–Nov 2026, 285 preprints said they used Nanopore PromethION, and 195 PacBio Revio.

Oxford Nanopore · High-throughput nanopore sequencer
285
preprints in the last 6 months
Change vs a year earlier+18%
Preprints since April 2025887
1.5xmore often
PacBio · HiFi long-read sequencer
195
preprints in the last 6 months
Change vs a year earlier+53%
Preprints since April 2025535

Revio is growing faster.

In Jun–Nov 2026 vs the previous year, as a share of all preprints, PacBio Revio grew 53% and Nanopore PromethION grew 18%.

RevioPromethION

Which preprints have used both PacBio Revio and Nanopore PromethION?

95 preprints since April 2025 say they used both PacBio Revio and Nanopore PromethION. That's 18% of the 535 preprints using Revio and 11% of the 887 using PromethION.

Which institutions use PacBio Revio and Nanopore PromethION most?

Labs at University of Washington, Arizona State University and University of California, Davis use PacBio Revio most; at Stanford University, University of Washington and Australian National University, Nanopore PromethION. The lab's institution is the corresponding author's.

Revio PacBio

Where the labs are

  • US47%
  • UK6%
  • China5%
  • Japan5%

Institutions using it most

  1. University of Washington15
  2. Arizona State University9
  3. University of California, Davis7
  4. Stanford University7

Fields

Genomics 203Evolutionary biology 67Microbiology 62Genetic and genomic medicine 28

PromethION Oxford Nanopore

Where the labs are

  • US34%
  • UK8%
  • Germany8%
  • Australia8%

Institutions using it most

  1. Stanford University16
  2. University of Washington14
  3. Australian National University9
  4. University of Copenhagen9

Fields

Genomics 283Microbiology 140Bioinformatics 63Evolutionary biology 55

How we count which preprints use each platform

An AI model reads each preprint in full — its text, its tables and its supplementary files — and lists the products the authors used. A preprint counts for a platform when that record says the lab used it in this work, not when it only analyzed data others made with it or only mentioned it. Each preprint counts once, by its first version, if it was first posted on bioRxiv or medRxiv in April 2025 or later. We read new preprints within days of posting, so the newest ones (through Nov 16, 2026) are already counted, but those days are not complete yet. Six-month counts and growth figures stop at Nov 12, 2026, the last day nearly every preprint has been read, and charts draw a quarter that is still being counted in a paler color. A preprint that used two platforms counts for both. This page counts how often each platform is used in preprints. It does not show which is better, or market share. Each title links to the preprint on bioRxiv or medRxiv; we show no preprint text and no author names. Updated daily, most recently on Nov 16, 2026.

Want to reach out to the labs using Revio or PromethION?

Get the PIs behind the preprints: institutions, labs, platforms they used, and how to reach them.

Institutions with the most preprints using either